基于质谱的蛋白质组学在骨肉瘤生物标志物发现中的研究进展：现状与未来方向。

Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction.

机构信息

Musculoskeletal Science and Translational Research (MSTR) Center, Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

出版信息

Int J Mol Sci. 2022 Aug 28;23(17):9741. doi: 10.3390/ijms23179741.

DOI:10.3390/ijms23179741

PMID:36077137

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9456544/

Abstract

Due to a lack of novel therapies and biomarkers, the clinical outcomes of osteosarcoma patients have not significantly improved for decades. The advancement of mass spectrometry (MS), peptide quantification, and downstream pathway analysis enables the investigation of protein profiles across a wide range of input materials, from cell culture to long-term archived clinical specimens. This can provide insight into osteosarcoma biology and identify candidate biomarkers for diagnosis, prognosis, and stratification of chemotherapy response. In this review, we provide an overview of proteomics studies of osteosarcoma, indicate potential biomarkers that might be promising therapeutic targets, and discuss the challenges and opportunities of mass spectrometric-based proteomics in future osteosarcoma research.

摘要

由于缺乏新的治疗方法和生物标志物，几十年来，骨肉瘤患者的临床结果并没有显著改善。质谱（MS）、肽定量和下游途径分析的进步使得可以研究从细胞培养到长期存档的临床标本等各种输入材料中的蛋白质谱。这可以深入了解骨肉瘤生物学，并确定用于诊断、预后和化疗反应分层的候选生物标志物。在这篇综述中，我们概述了骨肉瘤的蛋白质组学研究，指出了一些可能有希望成为治疗靶点的潜在生物标志物，并讨论了基于质谱的蛋白质组学在未来骨肉瘤研究中的挑战和机遇。